New TARGETED NANOSPHERE (TNS) platform and drug candidates that significantly enhance both existing and developing cancer (and other) therapeutics. NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company collaborating with the Children's Hospital Los Angeles (CHLA) as well as other US academic partners. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational capability.
Services
NVP is advancing a new generation of targeted nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) technology. These targeted nanospheres may provide a vast improvement in flexibility and choice for patients restricted by current treatment options including antibody, immunotherapy and ADC based products.
Reviews
Be the first to review Nanovalent Pharmaceuticals.
Write a Review